Suppr超能文献

慢性肾脏病 4 至 5 期患者骨质疏松的诊断与治疗:摒弃虚无主义,采取务实态度。

Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism.

机构信息

Division of Nephrology, University Hospitals Leuven, KU Leuven, Herestraat 49, B-3000, Leuven, Belgium.

Centre for Nephrology, Royal Free Campus, UCL Medical School, Rowland Hill Street, London, NW3 2PF, UK.

出版信息

Osteoporos Int. 2021 Dec;32(12):2397-2405. doi: 10.1007/s00198-021-05975-7. Epub 2021 Jun 15.

Abstract

The European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) CKD-MBD working group, in collaboration with the Committee of Scientific Advisors of the International Osteoporosis Foundation, published a position paper for the diagnosis and management of osteoporosis in patients with CKD stages 4-5D (eGFR < 30 ml/min 1.73 m). The present article reports and summarizes the main recommendations included in this 2021 document. The following areas are reviewed: diagnosis of osteoporosis; risk factors for fragility fractures; fracture risk assessment; intervention thresholds for pharmacological intervention; general and pharmacological management of osteoporosis; monitoring of treatment, and systems of care, all in patients with CKD stages 4-5D. Guidance is provided for clinicians caring for CKD stages 4-5D patients with osteoporosis, allowing for a pragmatic individualized diagnostic and therapeutic approach as an alternative to current variations in care and treatment nihilism.

摘要

欧洲肾脏协会-欧洲透析和移植协会(ERA-EDTA)慢性肾脏病矿物质和骨异常(CKD-MBD)工作组与国际骨质疏松基金会科学顾问委员会合作,发布了一份针对慢性肾脏病 4-5 期(eGFR < 30 ml/min/1.73 m )患者骨质疏松症的诊断和管理的立场文件。本文报告并总结了该 2021 年文件中的主要建议。以下领域进行了回顾:骨质疏松症的诊断;脆性骨折的危险因素;骨折风险评估;药物干预的干预阈值;慢性肾脏病 4-5 期患者的骨质疏松症的一般和药物治疗;以及治疗监测和护理系统。为治疗慢性肾脏病 4-5 期骨质疏松症患者的临床医生提供了指导,允许采用实用的个体化诊断和治疗方法,以替代当前护理和治疗虚无主义的差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验